January 31, 2023

These disclosures are from 13D filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of receiving more than 5% in any class of securities of a company. Subsequent changes in holdings or intentions must be reported in the amended filing. This content is from November 3 to November 9, 2022. Source: VerityData

increase in holdings

– Advertisement –

Varsha Therapeutics (Rain)

– Advertisement –

boxer capital increased its stake in the late-stage oncology-therapeutics company to 2,510,127 common shares. Boxer Capital purchased 972,212 general and 400,000 non-voting Rain Therapeutics shares for $5.83 each through a November 4 stock offering. After the offering closes on November 8, Boxer Capital holds a 9.99% stake in the pharmaceutical firm. Boxer Capital holds an additional 3,059,574 un-voting Rain Therapeutics shares, all of which 362,915 are excluded from Boxer Capital’s holding figures, as they are not converted into common shares due to ownership limits at 9.99% of Rain Therapeutics’ outstanding stock. can be.

New York Times (NYT)

– Advertisement –

Valueact Capital Increased its stake in the media company to 12,808,340 shares. ValueAct Capital bought 1,793,599 shares of the New York Times from September 27 to November 3 at per-share prices ranging from $28.23 to $33.10. No reason was given for the new investment, which gives ValueAct a 7.8% interest in The New York Times. In an August 2 regulatory filing, ValueAct said the New York Times stock was undervalued and represented an attractive investment opportunity. ValueAct said it held talks with New York Times executives and directors, and expects more conversations about the business, including the possibility of a ValueAct employee being on the New York Times board.

See also  Gap to Sell Greater China Business to Baozun for Up to $50 Million

Magnite (MgNi)

Edenbrook Capital increased its stake in the digital-advertising-services company to 6,893,079 shares. From September 8 to November 9, Addenbrook Capital bought 2,319,640 Magnite shares at prices ranging from $5.83 to $7.45. Edenbrook Capital now owns 5.2% of Magnite’s outstanding stock. Addenbrook Capital revealed that it has engaged with Magnite, and will likely continue to do so, discussing a variety of topics related to operations and strategy.

decrease in holdings

Hillman Solutions (HLMN)

CCMP Capital reduced its interest in the hardware-products provider to 51,205,500 shares. Via Rule 144—which includes the sale of restricted stock—CCMP Capital sold 8,400,000 Hillman shares at a price of $7.13 per share on November 7. No reason was given for the sale which now leaves CCMP with 26.3% of Hillman’s tradable stock. With respect to the sale, CCMP will abstain from selling any Hillman stock for the next 30 days.

Ventix Biosciences (VTYX)

third point reduced its interest in the clinical-stage pharmaceutical firm to 2,252,432 shares. On November 7 and 9, Third Point sold 2,060,402 Ventix shares at a price of $25.40 through $29.10. This included a block sale of two million shares on November 7 at a price of $25.94. After the disinvestment, Third Point owns only 4% of Ventix, well below the 5% threshold that would require reporting any future Ventix stock sales.

E-mail: [email protected]